Join the event


The International Cancer Screening Network (ICSN) is a consortium of countries, organizations, and experts interested in promoting multidisciplinary context-specific population cancer screening through evidence-based strategies. ICSN aims to evaluate implementation of cancer screening, and discuss methods for improving the quality and effectiveness of the programs.

Participation in the ICSN is open to any country or region that has initiated or is considering the implementation of a population-based cancer screening program.

ICSN members have formed interest groups focused on targeted research, data collection, and assessment of screening strategies tailored to the country context. Established interest groups that will meet preceding the ICSN 2023 include:

  • Cervical Cancer Screening
  • Colorectal Cancer Screening

(Start-up sessions of new working groups can also be organised by interested people)

ICSN 2023 will provide an opportunity for international experts to exchange knowledge, research methods, practice challenges, and results in the field of cancer screening; and, to prioritize, develop and move forward research projects through interest and working groups. ICSN 2023 sessions will include research relevant to:

  • Risk-based screening
  • Blood/Multi-cancer test
  • Screening as a research platform
  • New technologies and screening tests
  • Integrating primary and secondary prevention
  • Alternative approaches to implement screening as a public health intervention
  • Best practices
  • Communication issues
  • Hard-to-reach populations/Equity in cancer screening
  • Meeting the clinicians
  • Monitoring, evaluation and quality assurance

New screening programmes


After two years of health emergency, the next meeting of the International Cancer Screening Network, on June 21st-23rd, 2023, bringing together screening experts in several disciplines from all around the world, will offer the opportunity to share lessons learnt during the Covid 19 pandemic and to restart the screening activities with new impulses and renewed energy.

The event’s program will address various topics from new approaches to optimize screening and the potential contribution of new technologies to screening for established or new cancer sites.

The experience of using risk-based criteria for prioritization of delayed invitations showed that the adoption of this approach is expected to maximize the benefits and minimize the harms of screening and is now piloted in several settings.  Incorporating advances in genomics and biomarkers research in the screening process can offer new opportunities for a more precise risk assessment and for enhancing cost-effectiveness of screening. Moreover, a new era of early cancer detection with blood tests may change cancer screening paradigms.

Implementing new approaches requires collaboration between various stakeholders, policy makers and healthcare professionals, and the development of research efforts within ongoing screening programs.

It also requires the adoption of new and effective strategies to ensure equity of access and informed decisions for persons invited to attend cancer screening programs, avoiding exclusion of vulnerable sub-groups. Systematic monitoring and evaluation of screening programs’ performance will be necessary to support these innovations as well ensure quality of ongoing programs.

Other important issues addressed in this meeting include the integration of primary and secondary cancer prevention and communication with the screening target population as well as among health professionals.

Established interest working groups will also have the opportunity to meet again in person before the meeting to review achievements of their online activities during the past months and to plan new initiatives.

ICSN 2023 will be organized in Turin, North-West of Italy, and it will be again in person, four years since the last meeting in 2019. Apart from the session, the meeting will offer ample opportunities to network and interact with ICSN members. The health emergency has stranded us for two long years strongly affecting also our human relationships. Now it is time to restart. Welcome to Turin ICSN 2023!


February 25, 2023:
Submission Abstract deadline

March 31, 2023:
Notification of abstract acceptance

April 20, 2023:
Early Registration deadline for presenters of accepted abstracts

June 14, 2023:
Registration closes

June 21-23, 2023:
Conference Dates


1.30 pmWelcome
Welcome by the local authorities
Welcome by the Steering Committee
Welcome by the Planning Committee

2.10 pmIntroduction
Key note speech

2.30 pmPlenary Session 1
Risk-based Screening

4.15 pmCoffe Break
Country corner

5.00 pmConcurrent Session 1
Blood/Multi-cancer Test

5.00 pmConcurrent Session 2
Screening as a Research Platform
(Screening as an Opportunity to Contribute to Research)

9.00 amPlenary Session 2
New Technologies and Screening Tests

10.45 amCoffee Break
Country corner

11.30 amConcurrent Session 3
Integrating Primary and Secondary Prevention

11.30 amConcurrent Session 4
Comparing Alternative Approaches to Implement Screening as a Public Health Intervention

1.00 pmLunch and poster tour

2.15 pmPlenary Session 3
Best Practices

3.45 pmCoffee Break
Country corner

4.30 pmConcurrent Session 5
Communication Issues

4.30 pmConcurrent Session 6
Data System and Legal Framework

9.00 amPlenary Session 4
Hard-to-Reach Populations – Equity in Cancer Screening

10.45 amCoffe Break
Country corner

11.30 amConcurrent Session 7
Monitoring, Evaluation and Quality Assurance

11.30 amConcurrent Session 8
Screening and Clinical Medicine

1.00 pmLunch and poster tour

2.15 pmPlenary Session 5
New Screening Programmes

4.00 pmClosing remarks


(until April 20, 2023)
(after April 20, 2023)
Standard Delegate 650,00 € 750,00 €
Low Income Countries* 550,00 € 550,00 €
Social dinner 55,00 € 55,00 €

* Afghanistan, Burkina Faso, Burundi, Central African Republic, Chad, Congo, Dem. Rep., Eritrea, Ethiopia, Gambia, The Guinea, Guinea-Bissau, Korea, Dem. People’s Rep., Liberia, Madagascar, Malawi, Mali, Mozambique, Niger, Rwanda, Sierra Leone, Somalia, South Sudan, Sudan, Syrian Arab Republic, Togo, Uganda, Yemen, Rep., Zambia

All registration fees are VAT included.
Please, follow this link to register:


Please note that:

  • the registration fee includes all refreshments, including welcome reception
  • payment will be accepted by Credit Card or PayPal
  • registration fees must be paid in euros
  • the Social Conference Dinner is optional


Cancellation has to be made by e-mail to the Conference Secretariat ( If a cancellation is received before or on April 29, 2023 the registration fee will be reimbursed minus EUR 75,- handling charges. After this date, or if registrants fail to attend the conference for any reason whatsoever, regrettably no refund can be made.



  • Once you have submitted your abstract, you will receive an automatic email confirmation.
    If you do not receive an email, please email the Organizing Secretariat (
  • All abstracts will be reviewed, scored and accepted or rejected by the Scientific Committee.
    The decision of the Committee is final.
  • You will be notified of your submission’s acceptance status via e-mail by March 31, 2023.
  • If an abstract is accepted for presentation, the presenting author must attend the Conference to present the abstract. The presenting author will be required to register for the Conference by April 20, 2023 in order to have the abstract acceptance confirmed. If a presenting author is not registered by that date, the Scientific Committee will remove the abstract from the program.
  • Abstract presenters will be required to fund in full their own attendance at the conference (including conference registration and travel expenses) and should not accept to present an abstract if this is not possible.

Abstract submission has been postponed to March 6, 2023.



Mireille Broeders PhD

Chair (until Dec 2023)
Professor of Personalized Screening at Radboud University Medical Center, The Netherlands.
Currently chairs the ICSN.

Miriam Elfström PhD

Chair-elect (becomes Chair Jan 2024)
Karolinska Institute, Sweden.
Dr. Elfström is the Chair-Elect of ICSN and will be the next to take on the leadership of the network.


Anath Flugelman MD MPH – Technion – Ruth and Bruce Rappaport Faculty of Medicine, Israel

Andrea Burón MD PhD MPH  Hospital del Mar, Spain

Antonio Ponti MD MPH (formerly at) Cancer Prevention Center (CPO) – Turin, Italy

Aruna Kamineni PhD MPH – Kaiser Permanente Washington Health Research Institute, USA

Christine Campbell PhD MPH – University of Edinburgh, UK

David Weller PhD – University of Edinburgh, UK

Doug Perin JD MPH – Leidos Biomedical Research Inc./U.S. National Cancer Institute, USA

Elsebeth Lynge PhD – University of Copenhagen, Denmark

Harry de Koning MD PhD – Erasmus University Medical Center, The Netherlands

Jean-Luc Bulliard PhD – University of Lausanne, Switzerland

Linda Rabeneck MD MPH – Cancer Care Ontario, Canada

Mona Saraiya MD MPH – U.S. Centers for Disease Control and Prevention

Nereo Segnan MD MSc – (formerly at) Cancer Prevention Center (CPO) – Turin, Italy

Paul Doria-Rose DVM, PhD – U.S. National Cancer Institute, USA

Robert Smith PhD – American Cancer Society, USA


Livia Giordano – Epidemiologist, head  of the Epidemiology and Screening department, CPO-Azienda Ospedaliero Universitaria Città della Salute-Turin, Italy

Carlo Senore – Epidemiology and Screening Unit – CPO Piemonte – AOU Città della Salute e della Scienza, Turin, Italy

Silvia Deandrea – President, GISMa, Italian Group for Mammography Screening, Italy

Tiziano Maggino President, GISCi, Italian Cervical Cancer Screening Group, Italy

Paola Mantellini – Director, ONS, National Screening Observatory, Italy

Antonio Ponti – Epidemiologist, Epidemiology and Screening department, CPO-Azienda Ospedaliero Universitaria Città della Salute-Turin, Italy

Pietro Presti – Genaral Director, Fondazione Tempia, Italy

Nereo Segnan – Head of Screening and Cancer Registry at  CPO Piemonte “Città della Salute e della Scienza” University Hospital (1993-2017), Turin, Italy


Sermig – Arsenal of peace
Piazza Borgo Dora, 61
10152 – Turin, Italy
Phone: +39.011.4368566

It once was an arsenal of war, a factory of weapons, but, since 1983, the free work of thousands of people transformed it into an Arsenal of Peace.


Visa requirements

Information on Visa requirements can be found at

Travelling to Turin

For information on travelling to Turin please visit


Book your hotel accommodation at special rates by selecting the hotel that best suits you:

For any further assistance or request please contact our booking office:

Consorzio Turistico Incoming Experience
Via Berthollet 19,
10125 Turin (Italy)
Phone +39  0116505309

Copyright 2022 Prospero Multilab Srl. Tutti i diritti riservati.